If you're considering weight loss medications like the popular GLP-1 agonists — like semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound ... rules and fine print that most people only ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.

Eli Lilly and Company CEO David Ricks stands as President Donald Trump speaks about investing in America in the Cross Hall of the White House, Wednesday, April 30, 2025, in Washington. Eli Lilly's ...

Zepbound (tirzepatide) is a type of drug called a glucagon-like peptide-1 (GLP-1) receptor agonist. It has the same active ingredient as the type 2 diabetes medication Mounjaro. The Food and Drug ...